DelveInsight’s ‘Radiation-induced Esophagitis Market Insights, Epidemiology, and Market Forecast-2030’ report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of radiation-induced esophagitis (RIE) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The radiation-induced esophagitis (RIE) market report provides analysis regarding current treatment practices, emerging drugs like GC4419, potential therapies, market share of the individual therapies, and historical, current and forecasted RIE market size from 2017 to 2030, segmented by seven major markets.
The report also covers current radiation-induced esophagitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017–2030
Overview:
Radiation-induced esophagitis is a dose-limiting complication of thoracic external beam radiation. The risk of developing esophageal toxic effects depends on the radiation dose, radiation delivery method, and administration of chemotherapy. It rarely occurs in patients exposed to 30 Gy or less of radiation as per available literature.
Radiation therapy leads to mucosal damage, production of pro-inflammatory cytokines, and eventually cell death which leads to ulcerations of the esophageal mucosal lining. Radiation therapy causes cell DNA damage, leading to stress-related, pro-inflammatory cytokine production through various signaling pathways and ultimately causing mucosal damage and irritation. If severe, ulcerations of the mucosal wall can occur. Symptoms occur acutely, generally within the first 2 months. Patients typically present with nonspecific symptoms such as dysphagia and odynophagia.
Treatment:
This chapter covers the details of conventional and current medical therapies available for the treatment of radiation-induced esophagitis. It also provides the country-wise RIE treatment guidelines across the United States, Europe and Japan.
DelveInsight’s radiation-induced esophagitis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides RIE treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Epidemiology:
The radiation-induced esophagitis (RIE) epidemiology chapters provide insights about historical and current RIE patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. RIE epidemiology is segmented by the incidence of lung cancer by types, the stage-wise incidence of NSCLC, cases receiving CCRT/CRT, acute radiation-induced esophagitis (ARIE) by grade. Besides, the report includes a thorough analysis of all segments.
Radiation-induced esophagitis can be divided into two subtypes using a grading system are namely: acute and late. In the US, the cases of RIE were found to be 7,834 for grade 4, 926 for grade1, 8,508 for grade 2, 2,463 for grade 3, and 226 for grade 4, in 2017.
According to DelveInsight’s, the total prevalent population of RIE in seven major markets was 57,455 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, the United States accounted for the highest number of radiation-induced esophagitis cases.
This segment encloses the detailed analysis of the drugs in the radiation-induced esophagitis (RIE) pipeline. It also helps to understand the RIE clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Treatment is supportive care with adequate hydration and nutrition intake. Amifostine, an organic triphosphate, has been studied and shown to act as a radioprotector. Dietary modifications are also suggested. Moreover, Galera Therapeutics’ GC4419 is the only therapy in the pipeline.
The market size of radiation-induced esophagitis (RIE) is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest RIE market size. Among EU5 countries, Germany had the highest market size, with USD 3.22 million in 2017, while Spain had the smallest market size of RIE, with USD 1.89 million in 2017.
This section focuses on the rate of uptake of the potential drugs in the radiation-induced esophagitis (RIE) market or expected to get launched in the market during the study period 2017–2030. The analysis covers RIE market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of RIE market is anticipated to experience a positive shift in the coming years owing to the expected launch of GC-4419 (Galera Therapeutics).
Radiation-induced Esophagitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.
Pipeline Development Activities:
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning radiation-induced esophagitis.
To keep up with current market trends, we take KOLs and SME’s opinion working in radiation-induced esophagitis domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We have performed the competitive and market Intelligence analysis of the radiation-induced esophagitis Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
Market Insights:
What was the radiation-induced esophagitis (RIE) market share (%) distribution in 2017 and how it would look like in 2030?
Epidemiology Insights:
Which geography accounted for the largest radiation-induced esophagitis market size?
The United States accounted for the largest RIE market size.
What is forecasted radiation-induced esophagitis size in 2030?
DelveInsight estimates an increase in RIE Market Size during the study period, 2017–2030
What are the present radiation-induced esophagitis drivers?
Increasing incidence of cancers leading to more usage of radiation therapy, development of novel therapeutic approaches and scoring systems
What are the radiation-induced esophagitis market barriers?
Lack of epidemiology-based literature, Disease Rarity, Risk of Recurrence.
How many companies are developing drugs for radiation-induced esophagitis?
Currently, only one key pharma player is developing the drug for RIE.
Which are the leading companies in radiation-induced esophagitis market?
Key Player – Galera Therapeutics
How is epidemiology segmented for radiation-induced esophagitis?
Incidence of Lung Cancer by Types, Stage-wise Incidence of NSCLC, Cases receiving CCRT/CRT, Acute radiation-induced esophagitis (ARIE) by grade
1 Key Insights
2 Executive Summary of Radiation-induced Esophagitis (RIE)
3 SWOT Analysis for Radiation-induced Esophagitis
4 Radiation-induced Esophagitis Epidemiology Overview at a Glance
4.1 Patient Share (%) Distribution of Radiation-induced Esophagitis in 2017
4.2 Patient Share (%) Distribution of Radiation-induced Esophagitis in 2030
5 Radiation-induced Esophagitis Market Overview at a Glance
5.1 Market Share (%) Distribution of Radiation-induced Esophagitis in 2017
5.2 Market Share (%) Distribution of Radiation-induced Esophagitis in 2030
6 Disease Background and Overview
6.1 Introduction
6.2 Types
6.3 Symptoms
6.4 Grading
6.5 Pathophysiology
6.6 Diagnosis
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Total CRT Cases Suffering from ARIE in the 7MM
7.3 Assumptions and Rationale
8 Country Wise-Epidemiology of Radiation-induced Esophagitis
8.1 The United States
8.1.1 Incidence of Lung Cancer by Types in the US
8.1.2 Stage-wise Incidence of NSCLC in the US
8.1.3 Cases receiving CCRT/CRT in the US
8.1.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in the US
8.2 EU5 Countries
8.3 Germany
8.3.1 Incidence of Lung Cancer by Types in Germany
8.3.2 Stage-wise Incidence of NSCLC in Germany
8.3.3 Cases receiving CCRT/CRT in Germany
8.3.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Germany
8.4 France
8.4.1 Incidence of Lung Cancer by Types in France
8.4.2 Stage-wise Incidence of NSCLC in France
8.4.3 Cases receiving CCRT/CRT in France
8.4.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in France
8.5 Italy
8.5.1 Incidence of Lung Cancer by Types in Italy
8.5.2 Stage-wise Incidence of NSCLC in Italy
8.5.3 Cases receiving CCRT/CRT in Italy
8.5.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Italy
8.6 Spain
8.6.1 Incidence of Lung Cancer by Types in Spain
8.6.2 Stage-wise Incidence of NSCLC in Spain
8.6.3 Cases receiving CCRT/CRT in Spain
8.6.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Spain
8.7 The United Kingdom
8.7.1 Incidence of Lung Cancer by Types in the UK
8.7.2 Stage-wise Incidence of NSCLC in the UK
8.7.3 Cases receiving CCRT/CRT in the UK
8.7.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in the UK
8.8 Japan
8.8.1 Incidence of Lung Cancer by Types in Japan
8.8.2 Stage-wise Incidence of NSCLC in Japan
8.8.3 Cases receiving CCRT/CRT in Japan
8.8.4 Acute Radiation-induced Esophagitis (ARIE) by Grade in Japan
9 Treatment and Management
10 Case Study' Esophageal Stricture Following Radiation, Concurrent Immunochemotherapy, Treated With Hyperbaric Oxygen and Dilation'
11 Patient Journey
12 Unmet Needs
13 Emerging Therapies
13.1 GC4419: Galera Therapeutics, Inc.
13.1.1 Product Description
13.1.2 Clinical Development
14 Other Potential Therapies
15 Radiation-induced Esophagitis: Seven Major Market Analysis
15.1 Key Findings
1.2 Market Size of Radiation-induced Esophagitis in the 7MM
16 Market Outlook by Country
16.1 Assumption and Rationale
16.2 United States
16.2.1 The total market size of Radiation-induced Esophagitis (RIE)
16.2.2 Radiation-induced Esophagitis Market Size by Therapies
16.3 EU5 Countries
16.3.1 Germany
16.3.2 France
16.3.3 Italy
16.3.4 Spain
16.3.5 United Kingdom
16.4 Japan
16.4.1 The total market size of Radiation-induced Esophagitis
16.4.2 Radiation-induced Esophagitis Market Size by Therapies
17 Market Drivers
18 Market Barriers
19 Appendix
19.1 Report Methodology
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
List of Tables
Table 1: Summary of RIE Market, Epidemiology, and Key Events (2017–2030)
Table 2: RTOG/EORTC late esophagitis morbidity grading criteria
Table 3: Normal tissue tolerance of Therapeutic Irradiation: Traditional estimates
Table 4: Total cases of Radiation-induced Esophagitis in 7MM (2017–2030)
Table 5: Incidence of Lung Cancer by Types in the US (2017–2030)
Table 6: Stage-wise Incidence of NSCLC in the United States (2017–2030)
Table 7: Cases receiving CCRT/CRT in the United States (2017–2030)
Table 8: Acute Radiation-induced Esophagitis (ARIE) by Grade in the United States (2017–2030)
Table 9: Incidence of Lung Cancer by Types in Germany (2017–2030)
Table 10: Stage-wise Incidence of NSCLC in Germany (2017–2030)
Table 11: Cases receiving CCRT/CRT in Germany (2017–2030)
Table 12: Acute Radiation-induced Esophagitis (ARIE) by Grade in Germany (2017–2030)
Table 13: Incidence of Lung Cancer by Types in France (2017–2030)
Table 14: Stage-wise Incidence of NSCLC in France (2017–2030)
Table 15: Cases receiving CCRT/CRT in France (2017–2030)
Table 16: Acute Radiation-induced Esophagitis (ARIE) by Grade (2017–2030)
Table 17: Incidence of Lung Cancer by Types in Italy (2017–2030)
Table 18: Stage-wise Incidence of NSCLC in Italy (2017–2030)
Table 19: Cases receiving CCRT/CRT in Italy (2017–2030)
Table 20: Acute Radiation-induced Esophagitis (ARIE) by Grade in Italy (2017–2030)
Table 21: Incidence of Lung Cancer by Types in Spain (2017–2030)
Table 22: Stage-wise Incidence of NSCLC in Spain (2017–2030)
Table 23: Cases receiving CCRT/CRT in Spain (2017–2030)
Table 24: Acute Radiation-induced Esophagitis (ARIE) by Grade in Spain (2017–2030)
Table 25: Incidence of Lung Cancer by Types in the UK (2017–2030)
Table 26: Stage-wise Incidence of NSCLC in the UK (2017–2030)
Table 27: Cases receiving CCRT/CRT in the UK (2017–2030)
Table 28: Acute Radiation-induced Esophagitis (ARIE) by Grade in the UK (2017–2030)
Table 29: Incidence of Lung Cancer by Types in Japan (2017–2030)
Table 30: Stage-wise Incidence of NSCLC in Japan (2017–2030)
Table 31: Cases receiving CCRT/CRT in Japan (2017–2030)
Table 32: Optimal management of esophagitis
Table 33: GC4419, Clinical Trial Description, 2020
Table 34: 7 Major Market Size of RIE in USD Million (2017–2030)
Table 35: The US Market size of Radiation-induced Esophagitis in USD Million (2017–2030)
Table 36: The US market size of Radiation-induced Esophagitis by Therapies in USD Million (2017–2030)
Table 37: Germany Market size of Radiation-induced Esophagitis in USD Million (2017–2030)
Table 38: Germany market size of Radiation-induced Esophagitis by Therapies in USD Million (2017–2030)
Table 39: France Market size of Radiation-induced Esophagitis in USD Million (2017–2030)
Table 40: France market size of Radiation-induced Esophagitis by Therapies in USD Million (2017–2030)
Table 41: Italy Market size of Radiation-induced Esophagitis in USD Million (2017–2030)
Table 42: Italy market size of Radiation-induced Esophagitis by Therapies in USD Million (2017–2030)
Table 43: Spain Market size of Radiation-induced Esophagitis in USD Million (2017–2030)
Table 44: Spain market size of Radiation-induced Esophagitis by Therapies in USD Million (2017–2030)
Table 45: UK Market size of Radiation-induced Esophagitis in USD Million (2017–2030)
Table 46: UK market size of Radiation-induced Esophagitis by Therapies in USD Million (2017–2030)
Table 47: Japan Market size of Radiation-induced Esophagitis in USD Million (2017–2030)
Table 48: Japan market size of Radiation-induced Esophagitis by Therapies in USD Million (2017–2030)
List of Figures
Figure 1: SWOT Analysis
Figure 2: Total cases of Radiation-induced Esophagitis in 7MM (2017–2030)
Figure 3: Incidence of Lung Cancer by Types in the US (2017–2030)
Figure 4: Stage-wise Incidence of NSCLC in the United States (2017–2030)
Figure 5: Cases receiving CCRT/CRT in the United States (2017–2030)
Figure 6: Acute Radiation-induced Esophagitis (ARIE) by Grade in the United States (2017–2030)
Figure 7: Incidence of Lung Cancer by Types in Germany (2017–2030)
Figure 8: Stage-wise Incidence of NSCLC in Germany (2017–2030)
Figure 9: Cases receiving CCRT/CRT in Germany (2017–2030)
Figure 10: Acute Radiation-induced Esophagitis (ARIE) by Grade in Germany (2017–2030)
Figure 11: Incidence of Lung Cancer by Types in France (2017–2030)
Figure 12: Stage-wise Incidence of NSCLC in France (2017–2030)
Figure 13: Cases receiving CCRT/CRT in France (2017–2030)
Figure 14: Acute Radiation-induced Esophagitis (ARIE) by Grade in France (2017–2030)
Figure 15: Incidence of Lung Cancer by Types in Italy (2017–2030)
Figure 16: Stage-wise Incidence of NSCLC in Italy (2017–2030)
Figure 17: Cases receiving CCRT/CRT in Italy (2017–2030)
Figure 18: Acute Radiation-induced Esophagitis (ARIE) by Grade in Italy (2017–2030)
Figure 19: Incidence of Lung Cancer by Types in Spain (2017–2030)
Figure 20: Stage-wise Incidence of NSCLC in Spain (2017–2030)
Figure 21: Cases receiving CCRT/CRT in Spain (2017–2030)
Figure 22: Acute Radiation-induced Esophagitis (ARIE) by Grade in Spain (2017–2030)
Figure 23: Incidence of Lung Cancer by Types in the UK (2017–2030)
Figure 24: Stage-wise Incidence of NSCLC in the UK (2017–2030)
Figure 25: Cases receiving CCRT/CRT in the UK (2017–2030)
Figure 26: Acute Radiation-induced Esophagitis (ARIE) by Grade in the UK (2017–2030)
Figure 27: Incidence of Lung Cancer by Types in Japan (2017–2030)
Figure 28: Stage-wise Incidence of NSCLC in Japan (2017–2030)
Figure 29: Cases receiving CCRT/CRT in Japan (2017–2030)
Figure 30: Acute Radiation-induced Esophagitis (ARIE) by Grade in Japan (2017–2030)
Figure 31: Patient journey Radiation-induced Esophagitis
Figure 32: Unmet Needs of Radiation-induced Esophagitis
Figure 33: Seven Major Market Size of RIE in USD Million (2017–2030)
Figure 34: Market Size of Radiation-induced Esophagitis in the United States, USD Millions (2017–2030)
Figure 35: The US market size of Radiation-induced Esophagitis by therapies in USD Million (2017–2030)
Figure 36: Market Size of Radiation-induced Esophagitis in Germany, USD Millions (2017–2030)
Figure 37: Germany market size of Radiation-induced Esophagitis by therapies in USD Million (2017–2030)
Figure 38: Market Size of Radiation-induced Esophagitis in France, USD Millions (2017–2030)
Figure 39: France market size of Radiation-induced Esophagitis by therapies in USD Million (2017–2030)
Figure 40: Market Size of Radiation-induced Esophagitis in Italy, USD Millions (2017–2030)
Figure 41: Italy market size of Radiation-induced Esophagitis by therapies in USD Million (2017–2030)
Figure 42: Market Size of Radiation-induced Esophagitis in Spain, USD Millions (2017–2030)
Figure 43: Spain market size of Radiation-induced Esophagitis by therapies in USD Million (2017–2030)
Figure 44: Market Size of Radiation-induced Esophagitis in the UK, USD Millions (2017–2030)
Figure 45: The UK market size of Radiation-induced Esophagitis by therapies in USD Million (2017–2030)
Figure 46: Market Size of Radiation-induced Esophagitis in Japan, USD Millions (2017–2030)
Figure 47: Japan market size of Radiation-induced Esophagitis by therapies in USD Million (2017–2030)
Figure 48: Market Drivers
Figure 49:Market Barriers
Galera Therapeutics, Inc.
